Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome
Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patient...
Saved in:
Published in | The Journal of clinical investigation Vol. 82; no. 4; pp. 1415 - 1421 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Ann Arbor, MI
American Society for Clinical Investigation
01.10.1988
|
Subjects | |
Online Access | Get full text |
ISSN | 0021-9738 |
DOI | 10.1172/JCI113746 |
Cover
Abstract | Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha 2 and IFN gamma. The binding characteristics of the 125I-IFN alpha and gamma to PBM were analyzed to determine receptor numbers and dissociation constants. PBM from controls expressed 498 +/- 247 IFN alpha receptor sites/cell (n = 17). However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 +/- 235 (P less than 0.05) and 92 +/- 88 (P less than 0.001), respectively. This was consistent with elevated levels of serum acid-labile IFN alpha and cellular 2-5A synthetase activity in patients. Treatment of PBM from the AIDS patients with exogenous IFN alpha in vitro resulted in minimal 2-5A synthetase induction in comparison to controls. In contrast, the expression of IFN gamma receptors in ARC (n = 5) and AIDS (n = 4) patients remained normal. Thus the decrease in IFN alpha receptor expression and consequent hyporesponsiveness to IFN alpha raises the question of the usefulness of IFN alpha therapy in end-stage AIDS. The normal expression of IFN gamma receptors in AIDS patients suggests that IFN gamma may prove useful in attempts to provide immune reconstitution. |
---|---|
AbstractList | Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha 2 and IFN gamma. The binding characteristics of the 125I-IFN alpha and gamma to PBM were analyzed to determine receptor numbers and dissociation constants. PBM from controls expressed 498 +/- 247 IFN alpha receptor sites/cell (n = 17). However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 +/- 235 (P less than 0.05) and 92 +/- 88 (P less than 0.001), respectively. This was consistent with elevated levels of serum acid-labile IFN alpha and cellular 2-5A synthetase activity in patients. Treatment of PBM from the AIDS patients with exogenous IFN alpha in vitro resulted in minimal 2-5A synthetase induction in comparison to controls. In contrast, the expression of IFN gamma receptors in ARC (n = 5) and AIDS (n = 4) patients remained normal. Thus the decrease in IFN alpha receptor expression and consequent hyporesponsiveness to IFN alpha raises the question of the usefulness of IFN alpha therapy in end-stage AIDS. The normal expression of IFN gamma receptors in AIDS patients suggests that IFN gamma may prove useful in attempts to provide immune reconstitution. Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha 2 and IFN gamma. The binding characteristics of the 125I-IFN alpha and gamma to PBM were analyzed to determine receptor numbers and dissociation constants. PBM from controls expressed 498 +/- 247 IFN alpha receptor sites/cell (n = 17). However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 +/- 235 (P less than 0.05) and 92 +/- 88 (P less than 0.001), respectively. This was consistent with elevated levels of serum acid-labile IFN alpha and cellular 2-5A synthetase activity in patients. Treatment of PBM from the AIDS patients with exogenous IFN alpha in vitro resulted in minimal 2-5A synthetase induction in comparison to controls. In contrast, the expression of IFN gamma receptors in ARC (n = 5) and AIDS (n = 4) patients remained normal. Thus the decrease in IFN alpha receptor expression and consequent hyporesponsiveness to IFN alpha raises the question of the usefulness of IFN alpha therapy in end-stage AIDS. The normal expression of IFN gamma receptors in AIDS patients suggests that IFN gamma may prove useful in attempts to provide immune reconstitution.Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha 2 and IFN gamma. The binding characteristics of the 125I-IFN alpha and gamma to PBM were analyzed to determine receptor numbers and dissociation constants. PBM from controls expressed 498 +/- 247 IFN alpha receptor sites/cell (n = 17). However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 +/- 235 (P less than 0.05) and 92 +/- 88 (P less than 0.001), respectively. This was consistent with elevated levels of serum acid-labile IFN alpha and cellular 2-5A synthetase activity in patients. Treatment of PBM from the AIDS patients with exogenous IFN alpha in vitro resulted in minimal 2-5A synthetase induction in comparison to controls. In contrast, the expression of IFN gamma receptors in ARC (n = 5) and AIDS (n = 4) patients remained normal. Thus the decrease in IFN alpha receptor expression and consequent hyporesponsiveness to IFN alpha raises the question of the usefulness of IFN alpha therapy in end-stage AIDS. The normal expression of IFN gamma receptors in AIDS patients suggests that IFN gamma may prove useful in attempts to provide immune reconstitution. Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, the authors investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha sub(2) and IFN gamma . PBM from controls expressed 498 plus or minus 247 IFN alpha receptor sites/cell. However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 plus or minus 235 and 92 plus or minus 88, respectively. In contrast, the expression of IFN gamma receptors in ARC and AIDS patients remained normal. |
Author | Lau, A S Read, S E Williams, B R |
AuthorAffiliation | Division of Infectious Diseases, Hospital for Sick Children, Toronto, Ontario, Canada |
AuthorAffiliation_xml | – name: Division of Infectious Diseases, Hospital for Sick Children, Toronto, Ontario, Canada |
Author_xml | – sequence: 1 givenname: A S surname: Lau fullname: Lau, A S – sequence: 2 givenname: S E surname: Read fullname: Read, S E – sequence: 3 givenname: B R surname: Williams fullname: Williams, B R |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7272295$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/2971677$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkj1vFDEQhl0EhXxQ8AOQXCAkiiO212ufCwp0fCWKlAZqa9Y7e2e0a29s78H9e_bIceKjSDOj0fu8o7FnzslJiAEJec7ZG861uLpZXXNeaalOyBljgi-MrpZPyXnO3xjjUtbylJwKo7nS-oxs38fvIeF66qH4GGjsqA8FU4dprqAfN0CbqdAQC13DMABN6HAsMVH8MSbMee_ygW79Nu5z2SAFdz_5hC31wzCF2GLnncfgdjTvQpvigJfkSQd9xmeHfEG-fvzwZfV5cXv36Xr17nbhKinVQnJ0rJZGO-harNiStbxxjus5sEZB17SiVoC61Yo1rmnQaOC1QWGgW1amuiBvH_qOUzNg6zCUBL0dkx8g7WwEb_9Wgt_YddxaKYUye_-rgz_F-wlzsYPPDvseAsYpW72c_9MI8SjIa6aErNQMvvhzouMoh43M-suDDtlB3yUIzucjpoUWwtQzdvWAuRRzTthZ58uvFc7P8L3lzO6vwR6vYXa8_sfxu-f_7E9NCLqZ |
CODEN | JCINAO |
CitedBy_id | crossref_primary_10_1097_00006454_199607000_00002 crossref_primary_10_1182_blood_2008_11_190231 crossref_primary_10_1016_j_cytogfr_2017_04_004 crossref_primary_10_1089_aid_2007_0261 crossref_primary_10_1089_aid_1992_8_199 crossref_primary_10_1016_0168_8278_92_90173_M crossref_primary_10_1016_0090_1229_90_90082_2 crossref_primary_10_1089_jir_1998_18_209 crossref_primary_10_1016_j_cytogfr_2018_03_003 crossref_primary_10_1089_aid_1991_7_545 crossref_primary_10_1016_S0889_8553_05_70296_X crossref_primary_10_1007_BF01878118 crossref_primary_10_1016_S0025_7125_16_30378_9 crossref_primary_10_1016_S0923_2494_05_80052_5 crossref_primary_10_1089_aid_1990_6_1149 crossref_primary_10_1097_QAI_0000000000001280 crossref_primary_10_1016_j_vascn_2004_02_003 crossref_primary_10_1189_jlb_68_3_391 crossref_primary_10_1002_hep_1840130221 crossref_primary_10_1186_1742_4690_1_29 crossref_primary_10_1097_01_aids_0000233571_51899_ab crossref_primary_10_1073_pnas_94_21_11595 crossref_primary_10_1074_jbc_M304676200 crossref_primary_10_1089_jir_1996_16_127 crossref_primary_10_1128_JVI_76_16_8433_8445_2002 crossref_primary_10_1007_BF01299868 crossref_primary_10_1016_0268_960X_94_90112_0 crossref_primary_10_1128_JVI_01953_20 crossref_primary_10_1089_aid_1993_9_1115 |
ContentType | Journal Article |
Copyright | 1989 INIST-CNRS |
Copyright_xml | – notice: 1989 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 8FD FR3 H94 M7Z P64 7X8 5PM |
DOI | 10.1172/JCI113746 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biochemistry Abstracts 1 Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Biochemistry Abstracts 1 AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Virology and AIDS Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 1421 |
ExternalDocumentID | PMC442699 2971677 7272295 10_1172_JCI113746 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .55 .GJ 29K 2WC 3O- 53G 5GY 5RE 8F7 AAWTL AAYXX ABOCM ACGFO ACIHN ACNCT ACPRK ADBBV AEAQA AENEX AFFNX AHMBA AI. ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EJD EMB F5P FRP GROUPED_DOAJ GX1 HYE H~9 IAO IEA IHR INH IOF IPO J5H KQ8 L7B M1P MVM OK1 OVT P2P P6G RPM TEORI TR2 TVE VH1 VVN W2D WH7 WOQ WOW X7M YOC ZGI ZXP ZY1 .XZ 08G 08P 354 36B 5RS 7RV 7X7 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 AAKAS ABPMR ABUWG ADZCM AFCHL AFKRA ASPBG AVWKF AZFZN BBNVY BCR BCU BEC BENPR BHPHI BKEYQ BLC BPHCQ BVXVI CCPQU EBD EMOBN EX3 FEDTE FYUFA HCIFZ HMCUK HVGLF IHW IOV IQODW ISR ITC LK8 M5~ M7P N4W NAPCQ OBH OCB ODZKP OFXIZ OGEVE OHH OHT OVD OVIDX PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X S0X SJFOW SV3 UHU UKHRP XSB YFH YHG YKV ~H1 CGR CUY CVF ECM EIF NPM 7T5 7U9 8FD FR3 H94 M7Z P64 7X8 5PM |
ID | FETCH-LOGICAL-c3446-41ec05497cafde3080d1bcc17bcc0b6afbd256ae7d760bcbbe97a159e29af8393 |
ISSN | 0021-9738 |
IngestDate | Thu Aug 21 13:57:58 EDT 2025 Fri Sep 05 13:44:39 EDT 2025 Thu Sep 04 18:56:53 EDT 2025 Tue Aug 05 11:38:39 EDT 2025 Mon Jul 21 09:14:06 EDT 2025 Thu Apr 24 23:02:32 EDT 2025 Tue Jul 01 01:43:20 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Human Immunopathology Enzyme Alpha interferon AIDS Hemopathy Blood Infection Mononuclear cell Viral disease (2',5')A-Synthetase AIDS related complex Quantitative analysis Gamma interferon Biological receptor |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3446-41ec05497cafde3080d1bcc17bcc0b6afbd256ae7d760bcbbe97a159e29af8393 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | http://www.jci.org/articles/view/113746/files/pdf |
PMID | 2971677 |
PQID | 15062436 |
PQPubID | 23462 |
PageCount | 7 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_442699 proquest_miscellaneous_78454922 proquest_miscellaneous_15062436 pubmed_primary_2971677 pascalfrancis_primary_7272295 crossref_citationtrail_10_1172_JCI113746 crossref_primary_10_1172_JCI113746 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 19881001 |
PublicationDateYYYYMMDD | 1988-10-01 |
PublicationDate_xml | – month: 10 year: 1988 text: 19881001 day: 1 |
PublicationDecade | 1980 |
PublicationPlace | Ann Arbor, MI |
PublicationPlace_xml | – name: Ann Arbor, MI – name: United States |
PublicationTitle | The Journal of clinical investigation |
PublicationTitleAlternate | J Clin Invest |
PublicationYear | 1988 |
Publisher | American Society for Clinical Investigation |
Publisher_xml | – name: American Society for Clinical Investigation |
References | 6422299 - N Engl J Med. 1984 Apr 5;310(14):883-9 6712031 - Ann Intern Med. 1984 May;100(5):671-6 6229182 - Am J Med. 1984 Jan;76(1):95-100 6689734 - N Engl J Med. 1984 Jan 5;310(1):15-8 2996405 - Ann Intern Med. 1985 Nov;103(5):714-8 6086635 - J Biol Chem. 1984 Aug 10;259(15):9456-60 14450081 - Nature. 1962 May 5;194:495-6 6314645 - Virology. 1983 Oct 15;130(1):195-203 6189183 - Science. 1983 May 20;220(4599):868-71 6254391 - Anal Biochem. 1980 Sep 1;107(1):220-39 3009549 - J Clin Invest. 1986 May;77(5):1632-8 2411826 - J Infect Dis. 1985 Sep;152(3):466-72 6283974 - Ann Intern Med. 1982 Jun;96(6 Pt 1):700-4 2993441 - J Infect Dis. 1985 Sep;152(3):457-65 2940085 - Eur J Biochem. 1986 May 15;157(1):187-93 6327298 - Eur J Biochem. 1984 May 2;140(3):461-7 6318629 - Ann Intern Med. 1984 Jan;100(1):92-106 2857946 - Lancet. 1985 Mar 16;1(8429):602-4 6835320 - N Engl J Med. 1983 May 5;308(18):1071-6 2582258 - N Engl J Med. 1985 Jul 11;313(2):79-84 6979709 - N Engl J Med. 1982 Jul 22;307(4):232-6 3872068 - Am J Med. 1985 Mar;78(3):417-22 3008172 - Prog Clin Biol Res. 1985;202:405-13 6410234 - N Engl J Med. 1983 Sep 8;309(10):583-6 6143040 - Lancet. 1984 Mar 31;1(8379):698-702 2415141 - Annu Rev Immunol. 1985;3:477-500 3838854 - Am J Med. 1985 May;78(5):737-41 6224088 - N Engl J Med. 1983 Aug 25;309(8):453-8 6606643 - J Clin Immunol. 1983 Oct;3(4):332-40 6301456 - Biochem Biophys Res Commun. 1983 Jan 27;110(2):537-44 6125777 - Lancet. 1982 Sep 18;2(8299):631-3 6283973 - Ann Intern Med. 1982 Jun;96(6 Pt 1):693-700 6606691 - J Infect Dis. 1983 Dec;148(6):962-6 6439741 - J Clin Invest. 1984 Dec;74(6):2089-96 6200936 - Science. 1984 May 4;224(4648):500-3 6172066 - Ann Intern Med. 1982 Jan;96(1):80-93 7119475 - J Infect Dis. 1982 Oct;146(4):451-9 |
References_xml | – reference: 6125777 - Lancet. 1982 Sep 18;2(8299):631-3 – reference: 6979709 - N Engl J Med. 1982 Jul 22;307(4):232-6 – reference: 6189183 - Science. 1983 May 20;220(4599):868-71 – reference: 6283973 - Ann Intern Med. 1982 Jun;96(6 Pt 1):693-700 – reference: 3872068 - Am J Med. 1985 Mar;78(3):417-22 – reference: 6439741 - J Clin Invest. 1984 Dec;74(6):2089-96 – reference: 2940085 - Eur J Biochem. 1986 May 15;157(1):187-93 – reference: 3008172 - Prog Clin Biol Res. 1985;202:405-13 – reference: 2411826 - J Infect Dis. 1985 Sep;152(3):466-72 – reference: 6314645 - Virology. 1983 Oct 15;130(1):195-203 – reference: 3009549 - J Clin Invest. 1986 May;77(5):1632-8 – reference: 6410234 - N Engl J Med. 1983 Sep 8;309(10):583-6 – reference: 3838854 - Am J Med. 1985 May;78(5):737-41 – reference: 2993441 - J Infect Dis. 1985 Sep;152(3):457-65 – reference: 6689734 - N Engl J Med. 1984 Jan 5;310(1):15-8 – reference: 6301456 - Biochem Biophys Res Commun. 1983 Jan 27;110(2):537-44 – reference: 2415141 - Annu Rev Immunol. 1985;3:477-500 – reference: 6283974 - Ann Intern Med. 1982 Jun;96(6 Pt 1):700-4 – reference: 2996405 - Ann Intern Med. 1985 Nov;103(5):714-8 – reference: 6318629 - Ann Intern Med. 1984 Jan;100(1):92-106 – reference: 14450081 - Nature. 1962 May 5;194:495-6 – reference: 6835320 - N Engl J Med. 1983 May 5;308(18):1071-6 – reference: 6422299 - N Engl J Med. 1984 Apr 5;310(14):883-9 – reference: 6224088 - N Engl J Med. 1983 Aug 25;309(8):453-8 – reference: 6712031 - Ann Intern Med. 1984 May;100(5):671-6 – reference: 6327298 - Eur J Biochem. 1984 May 2;140(3):461-7 – reference: 6229182 - Am J Med. 1984 Jan;76(1):95-100 – reference: 6143040 - Lancet. 1984 Mar 31;1(8379):698-702 – reference: 6200936 - Science. 1984 May 4;224(4648):500-3 – reference: 6606691 - J Infect Dis. 1983 Dec;148(6):962-6 – reference: 6606643 - J Clin Immunol. 1983 Oct;3(4):332-40 – reference: 6172066 - Ann Intern Med. 1982 Jan;96(1):80-93 – reference: 7119475 - J Infect Dis. 1982 Oct;146(4):451-9 – reference: 2857946 - Lancet. 1985 Mar 16;1(8429):602-4 – reference: 6086635 - J Biol Chem. 1984 Aug 10;259(15):9456-60 – reference: 2582258 - N Engl J Med. 1985 Jul 11;313(2):79-84 – reference: 6254391 - Anal Biochem. 1980 Sep 1;107(1):220-39 |
SSID | ssj0014454 |
Score | 1.4818805 |
Snippet | Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1415 |
SubjectTerms | 2',5'-Oligoadenylate Synthetase - metabolism acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - blood Acquired Immunodeficiency Syndrome - enzymology Adult AIDS-Related Complex - enzymology AIDS-Related Complex - metabolism alpha -interferon Biological and medical sciences Blood Physiological Phenomena Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Interferon Type I - metabolism Interferon-gamma - metabolism leukocytes (mononuclear) Leukocytes, Mononuclear - classification Leukocytes, Mononuclear - enzymology Leukocytes, Mononuclear - metabolism Male Medical sciences Receptors, Immunologic - analysis Receptors, Immunologic - metabolism Receptors, Interferon |
Title | Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome |
URI | https://www.ncbi.nlm.nih.gov/pubmed/2971677 https://www.proquest.com/docview/15062436 https://www.proquest.com/docview/78454922 https://pubmed.ncbi.nlm.nih.gov/PMC442699 |
Volume | 82 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVgCDQJIb4mCgwsxANSFdbEbpw8wgBtg_EAm7S3yl-BSjSpurSa9uu5N3acZnQS8JJWseukOSfWtX3PMSGvDROGGSMjNc5inK2yUSYzHhUaxh6s0CPNUOB8_DU9OOVHZ-OzLpW3UZfU6q2-3Kgr-R9U4RzgiirZf0A2NAon4DvgC0dAGI5_hfEHGEIv3GbyPu5D94dFYReYY4wq2qFa1sOyqoc_5Gwmh9C92XmNJt8XPgG2SXRcTVdVm_AoNeYGQxg6ReVIZSxaTDT6zE3mBp2yrIlpg85y2tl3dOv8X-TSdUUhAP3mGfa9E0SsTwC99-mMxsn0sizkt3UqgTjKhXNuaXvaLFljFF_rNmPuNJ1_9ucC_WGP9g_jmAk3V7mG63zWAJugDZbfDKbvne1LbpJbiRBuFf_wc1hk4nzsTbrdrXrjKbjmXrjiNrntG-kFLnfn8hyeZuE2P9k0OrmaZLsWtZzcJ_c8NPSd484DcsOWD8mdY59Q8Yis-hSiVUE7CtGGQhQoRIFCtKEQbSlEOwrBTyhSCD-BQrSlEL1KIdpS6DE5_fTxZP8g8ltxRJrBSxvx2GoI7nOhZWEsg2GGiZXWsYDDSKWyUAZiZ2mFEelIaaVsLiREyjbJZQExONshW2VV2ieEJiqT-SjVLOMZH-epTEWBq-VQVTET6wF50z7nifY-9bhdyq9JM14VySSAMyCvQtW5M2fZVGm3B1aoiSkIST4ekJcteBPoWnG9TJa2Wp5P0Hwz4Sy9voaAf8DzJBmQHQd2aNyTZkDSHgtCObq690vK6c_G3Z2juDx_el2Lz8h29749J1v1Yml3IS6u1YuG3b8BATO_OA |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Downregulation+of+interferon+alpha+but+not+gamma+receptor+expression+in+vivo+in+the+acquired+immunodeficiency+syndrome&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Lau%2C+A+S&rft.au=Read%2C+S+E&rft.au=Williams%2C+B+R&rft.date=1988-10-01&rft.issn=0021-9738&rft.volume=82&rft.issue=4&rft.spage=1415&rft_id=info:doi/10.1172%2FJCI113746&rft_id=info%3Apmid%2F2971677&rft.externalDocID=2971677 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon |